
Opinion|Videos|December 23, 2024
Early Intervention and Personalized Frontline Therapies in Multiple Myeloma
Author(s)Shaji Kumar, MD
A panelist discusses how clinicians are navigating the evolving landscape of multiple myeloma treatment, from considering early intervention in high-risk smoldering cases to personalizing initial therapy choices between triplet and quadruplet regimens.
Advertisement
Video content above is prompted by the following:
- How are you approaching patients with high-risk smoldering multiple myeloma, particularly in considering early intervention before traditional CRAB (hypercalcemia, renal dysfunction, anemia, bone disease) criteria are met?
- What is your approach to personalizing first-line therapy selection among VRd (bortezomib, lenalidomide, and dexamethasone), KRd (carfilzomib, lenalidomide, and dexamethasone), and Dara-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone), considering the emerging quadruplet regimens?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Withdrawal of Aid Could Cause Millions of Lives Lost to HIV
2
EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy
3
Recent FDA Approvals Expand Dermatology Options for Patients With Skin of Color
4
FDA Approves Second Generic Mifepristone Pill for Abortion
5